At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4007 Pharmacy
Not Yet Opened 09-29 16:00:00 EDT
979.01
-5.94
-0.60%
High986.21Low968.84Vol465.37M
Open984.01D1 Closing984.95Amplitude1.76%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O12.56BT/O Rate--Tradable Shares0.00
P/B5.683464ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Chordia Therapeutics Secures AMED Grant to Accelerate Global Development of Rogocekib
TIPRANKS  ·  10:52
Chordia Therapeutics Secures AMED Grant to Accelerate Global Development of Rogocekib
IHH Healthcare's Recent Weakness Likely Offers a Buying Opportunity
Dow Jones  ·  10:11
IHH Healthcare's Recent Weakness Likely Offers a Buying Opportunity
Prescient Therapeutics Issues New Class of Long-Dated Unquoted Options
TIPRANKS  ·  09:17
Prescient Therapeutics Issues New Class of Long-Dated Unquoted Options
Prescient Therapeutics Seeks ASX Quotation for 73.8 Million New Shares
TIPRANKS  ·  08:22
Prescient Therapeutics Seeks ASX Quotation for 73.8 Million New Shares
Eli Lilly reports results from TRIUMPH-2 Phase 3 trial
TIPRANKS  ·  06:10
Eli Lilly reports results from TRIUMPH-2 Phase 3 trial
Lilly's Experimental Drug Cuts Weight by 21% in Diabetes Trial
Reuters  ·  06:06
Lilly's Experimental Drug Cuts Weight by 21% in Diabetes Trial
Eli Lilly - Retatrutide 12 Mg Results in 49.6 Lb (20.8%) Weight Loss over 80 Weeks
THOMSON REUTERS  ·  06:00
Eli Lilly - Retatrutide 12 Mg Results in 49.6 Lb (20.8%) Weight Loss over 80 Weeks
Lilly's Triple Agonist, Retatrutide, Delivered Substantial Weight Loss and A1c Reduction, Underscoring Its Potential Promise for People with Obesity and Type 2 Diabetes
THOMSON REUTERS  ·  06:00
Lilly's Triple Agonist, Retatrutide, Delivered Substantial Weight Loss and A1c Reduction, Underscoring Its Potential Promise for People with Obesity and Type 2 Diabetes
Eli Lilly - to Submit Biologics License Application for Retatrutide in Q1 2027
THOMSON REUTERS  ·  06:00
Eli Lilly - to Submit Biologics License Application for Retatrutide in Q1 2027
Eli Lilly - 59.5% of Retatrutide 12 Mg Participants no Longer Meet Bmi Criteria for Obesity
THOMSON REUTERS  ·  06:00
Eli Lilly - 59.5% of Retatrutide 12 Mg Participants no Longer Meet Bmi Criteria for Obesity
Universe Pharmaceuticals Files $200 Million Mixed Shelf
MT Newswires Live  ·  05:24
Universe Pharmaceuticals Files $200 Million Mixed Shelf
Aspire Biopharma Dismisses Auditor Turner Stone, Taps CBIZ as Replacement
Reuters  ·  05:15
Aspire Biopharma Dismisses Auditor Turner Stone, Taps CBIZ as Replacement
SenesTech CEO Michael Edell Acquires Common Shares Valued at $1,288.80
Reuters  ·  05:08
SenesTech CEO Michael Edell Acquires Common Shares Valued at $1,288.80
Xeris Biopharma COO Kevin McCulloch Sells $250,000 in Common Shares
Reuters  ·  05:00
Xeris Biopharma COO Kevin McCulloch Sells $250,000 in Common Shares
Zoetis Inc. Stock Underperforms Tuesday When Compared to Competitors
Dow Jones  ·  04:59
Zoetis Inc. Stock Underperforms Tuesday When Compared to Competitors
Stablecoin Development Addresses Recent Unusual Stock Trading Activity
TIPRANKS  ·  04:50
Stablecoin Development Addresses Recent Unusual Stock Trading Activity
Citius Oncology Holds Annual Shareholder Meeting
Reuters  ·  04:31
Citius Oncology Holds Annual Shareholder Meeting
Stablecoin Development Corp - Becomes Aware of UnUsUaL Trading Activity in Common Stock on Sept 29, 2026 - SEC Filing
THOMSON REUTERS  ·  04:17
Stablecoin Development Corp - Becomes Aware of UnUsUaL Trading Activity in Common Stock on Sept 29, 2026 - SEC Filing
Stablecoin Development Corp - Announces no Material Development or Other Reason for UnUsUaL Market Action - SEC Filing
THOMSON REUTERS  ·  04:17
Stablecoin Development Corp - Announces no Material Development or Other Reason for UnUsUaL Market Action - SEC Filing
Larimar Therapeutics appoints John Harlow as COO
TIPRANKS  ·  04:15
Larimar Therapeutics appoints John Harlow as COO

Introduction

Company Name.
BK4007
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--